Fintel reports that on April 20, 2023, Needham reiterated coverage of Shattuck Labs (NASDAQ:STTK) with a Buy recommendation.
Analyst Price Forecast Suggests 504.71% Upside
As of April 6, 2023, the average one-year price target for Shattuck Labs is $16.93. The forecasts range from a low of $9.09 to a high of $29.40. The average price target represents an increase of 504.71% from its latest reported closing price of $2.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Shattuck Labs is $0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -$2.54.
What are Other Shareholders Doing?
Federated Hermes holds 1K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing an increase of 65.69%. The firm increased its portfolio allocation in STTK by 143.60% over the last quarter.
VBINX - Vanguard Balanced Index Fund Investor Shares holds 25K shares representing 0.06% ownership of the company. No change in the last quarter.
Bridgeway Capital Management holds 85K shares representing 0.20% ownership of the company. In it's prior filing, the firm reported owning 110K shares, representing a decrease of 29.38%. The firm decreased its portfolio allocation in STTK by 36.30% over the last quarter.
Charles Schwab Investment Management holds 21K shares representing 0.05% ownership of the company. No change in the last quarter.
CSCVX - CornerCap Small-Cap Value Fund Advisor Class holds 27K shares representing 0.06% ownership of the company.
What is the Fund Sentiment?
There are 100 funds or institutions reporting positions in Shattuck Labs. This is a decrease of 24 owner(s) or 19.35% in the last quarter. Average portfolio weight of all funds dedicated to STTK is 0.05%, an increase of 24.51%. Total shares owned by institutions decreased in the last three months by 4.46% to 20,702K shares. 
The put/call ratio of STTK is 0.05, indicating a bullish outlook.
Shattuck Labs Background Information
(This description is provided by the company.)
Shattuck Labs, Inc. operates as a clinical-stage biotechnology company . The Company focuses on developing a novel class of biologic medicines for the treatment of cancer and autoimmune diseases. Shattuck Labs serves customers in the State of Texas.
See all Shattuck Labs regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
